Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
CytomX Therapeutics Inc (CTMX)
NASDAQ:CTMX
CytomX Therapeutics (CTMX) Stock Price & Analysis
538 Followers
CTMX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.04 - $5.85
Previous Close$1.38
Volume426.97K
Average Volume (3M)7.11M
Market Cap
$107.53M
Enterprise Value-$29.88M
Total Cash (Recent Filing)$150.28M
Total Debt (Recent Filing)$12.87M
Price to Earnings (P/E)6.9
Beta1.36
Next Earnings
Aug 07, 2024EPS Estimate
-$0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.20
Shares Outstanding77,919,369
10 Day Avg. Volume2,563,894
30 Day Avg. Volume7,113,310
Standard Deviation0.20
R-Squared0.09
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)-2.05
Price to Sales (P/S)2.42
Price to Cash Flow (P/CF)-1.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-0.25
Enterprise Value/Gross Profit-0.30
Enterprise Value/Ebitda-2.11
Forecast
1Y Price Target
$5.32Price Target Upside285.51% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
CytomX Therapeutics News
PremiumCompany Announcements
CytomX Therapeutics Appoints Chris Ogden as New CFO
Bulls Say, Bears Say
Bulls Say
Clinical DataInitial CX-904 data is encouraging, particularly in pancreatic cancer, which has historically faced numerous clinical challenges.
CollaborationsCTMX recently announced entering into a supply agreement and collaboration with Merck to assess CX-801 in combination with pembrolizumab in a variety of solid tumors.
Financial PerformanceCTMX reported a net gain of $13.8M or $0.17/share, above the estimate of $0.01 due to higher than expected revenue recognition, including $10M of milestones earned under the Astellas collaboration.
Bears Say
Clinical DataMore data is required to see evidence of trends by tumor type and dose level before becoming more positive on the stock.
Clinical TrialsThe Probody platform may fail in clinical trials.
Stock PerformanceThe net reaction to the initial Phase 1a data presentation was a stock drop of up to 45% during the earnings call.
---
Ownership Overview
44.25% Insiders
7.69% Mutual Funds
7.90% Other Institutional Investors
40.15% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CTMX FAQ
What was CytomX Therapeutics Inc’s price range in the past 12 months?
CytomX Therapeutics Inc lowest stock price was $1.04 and its highest was $5.85 in the past 12 months.
What is CytomX Therapeutics Inc’s market cap?
Currently, no data Available
When is CytomX Therapeutics Inc’s upcoming earnings report date?
CytomX Therapeutics Inc’s upcoming earnings report date is Aug 07, 2024 which is in 16 days.
How were CytomX Therapeutics Inc’s earnings last quarter?
CytomX Therapeutics Inc released its earnings results on May 08, 2024. The company reported $0.17 earnings per share for the quarter, beating the consensus estimate of -$0.102 by $0.272.
Is CytomX Therapeutics Inc overvalued?
According to Wall Street analysts CytomX Therapeutics Inc’s price is currently Undervalued.
Does CytomX Therapeutics Inc pay dividends?
CytomX Therapeutics Inc does not currently pay dividends.
What is CytomX Therapeutics Inc’s EPS estimate?
CytomX Therapeutics Inc’s EPS estimate is -$0.1.
How many shares outstanding does CytomX Therapeutics Inc have?
CytomX Therapeutics Inc has 77,919,370 shares outstanding.
What happened to CytomX Therapeutics Inc’s price movement after its last earnings report?
CytomX Therapeutics Inc reported an EPS of $0.17 in its last earnings report, beating expectations of -$0.102. Following the earnings report the stock price went down -51.313%.
Which hedge fund is a major shareholder of CytomX Therapeutics Inc?
Among the largest hedge funds holding CytomX Therapeutics Inc’s share is Platinum Investment Management. It holds CytomX Therapeutics Inc’s shares valued at N/A.
---
CytomX Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.32 (285.51% Upside)
$5.32 (285.51% Upside)
Blogger Sentiment
Bullish
CTMX Sentiment 75%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 635.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 2.1%
Last 30 Days ▲ 1.4%
Last 30 Days ▲ 1.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-24.17%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-21.29%
Trailing 12-Months
Company Description
CytomX Therapeutics Inc
CytomX Therapeutics, Inc. engages in the development of antibody therapeutics for the treatment of cancer based on its Probody therapeutic technology platform. Its pipeline includes immunotherapies, probody drug conjugates, T cell engaging bispecifics, and other multiple programs. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.
---
CTMX Earnings Call
Q1 2024
0:00 / 0:00
---
CTMX Stock 12 Month Forecast
Average Price Target
$5.32
▲(285.51% Upside)
Technical Analysis
Amneal Pharmaceuticals
―
Arvinas Holding Company
―
Rocket Pharmaceuticals
―
Intellia Therapeutics
―
Best Analysts Covering CTMX
1 Year
1 Year Success Rate
4/9 ratings generated profit
1 Year Average Return
-11.99%
upgraded a buy rating 2 months ago
Copying Robert Driscoll's trades and holding each position for 1 Year would result in 44.44% of your transactions generating a profit, with an average return of -11.99% per trade.
---